Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

March 20, 2024

https://www.globenewswire.com/news-release/2024/03/20/2849426/0/en/Celularity-Submits-Request-to-U-S-FDA-for-Orphan-Drug-Designation-for-PDA-002-Asset-Treating-Facioscapulohumeral-Muscular-Dystrophy.html

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ:CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy (FSHD).

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.